BioMarin's PALYNZIQ Receives FDA Approval for Adolescents with PKU The FDA has approved BioMarin's PALYNZIQ for adolescents aged 12 and up, providing a crucial treatment option for individuals with phenylketonuria (PKU).

BioMarin's PALYNZIQ Receives FDA Approval for Adolescents with PKU #United_States #San_Rafael #BioMarin #PKU #PALYNZIQ

FDA Grants Priority Review for BioMarin's PALYNZIQ Application to Treat Adolescents with PKU BioMarin's PALYNZIQ has received FDA's Priority Review status to extend its use in treating adolescents aged 12-17 with phenylketonuria.

FDA Grants Priority Review for BioMarin's PALYNZIQ Application to Treat Adolescents with PKU #United_States #San_Rafael #BioMarin #PKU #PALYNZIQ

BioMarin Pharmaceutical Announces Third Quarter 2025 Financial Results and Strategic Developments In its latest financial report, BioMarin Pharmaceutical showcases impressive growth and strategic portfolio realignment, highlighting key therapies and future initiatives.

BioMarin Pharmaceutical Announces Third Quarter 2025 Financial Results and Strategic Developments #United_States #San_Rafael #BioMarin_Pharmaceutical #VOXZOGO #PALYNZIQ

BioMarin's PALYNZIQ Shows Efficacy in Phase 3 Study for PKU Adolescents at ICIEM BioMarin Pharmaceutical shares promising Phase 3 data for PALYNZIQ, showing significant efficacy in lowering blood Phe levels among adolescents with PKU.

BioMarin's PALYNZIQ Shows Efficacy in Phase 3 Study for PKU Adolescents at ICIEM #USA #San_Rafael #BioMarin #PALYNZIQ #Phenylketonuria

BioMarin Pharmaceuticals Delivers Strong Q1 Results and Maintains Full-Year Projections for 2025 BioMarin Pharmaceutical Inc. reported substantial financial gains in Q1 2025, reaffirming its full-year guidance with a strong outlook for growth and innovative therapy launches.

BioMarin Pharmaceuticals Delivers Strong Q1 Results and Maintains Full-Year Projections for 2025 #United_States #San_Rafael #BioMarin #VOXZOGO #PALYNZIQ

@PKU_Ireland continue to wait for HTA decision on #Palynziq for #PKU 3 yrs after full submission to
@INFO_NCPE

So grateful Colm, Emer, Chloe, David for highlighting the frustration felt by so many of us in the PKU community.
#IndividualisedCare #LifeLongCare

PressReader.com - Digital Newspaper & Magazine Subscriptions Digital newsstand featuring 7000+ of the world’s most popular newspapers & magazines. Enjoy unlimited reading on up to 5 devices with 7-day free trial.

"HSE could save money if it paid for this drug" #Palynziq #HTA #EnzymeReplacementTherapy #PKU

pressreader.com/article/2822...